Akeso’s bispecific antibody ivonescimab has been included in FirstWord Pharma’s “Spotlight On: The Drugs That Will Shape 2026” list of key drugs poised to influence the global pharmaceutical landscape.

• Mechanism: Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody, developed by Akeso/Summit Therapeutics.
• Significance: It is the only drug on the list originating from a Chinese innovative pharmaceutical company’s independent R&D programme.
• Market Context: The FirstWord Pharma list includes 20 transformative drug candidates from companies worldwide, highlighting innovations across therapeutic areas.

This summary is based on a press release issued by Akeso, Inc.